Dynavax Technologies Corporation (NASDAQ:DVAX) Files An 8-K Other Events
Item 8.01. Other Events.
SUPPLEMENT TO PROXY STATEMENT
for the
ANNUAL MEETING OF STOCKHOLDERS
To the Stockholders of Dynavax Technologies Corporation:
Notice is hereby given that Dynavax Technologies Corporation
(Dynavax or the Company) intends to adjourn the Annual Meeting of
Stockholders, originally scheduled to be held on Wednesday, May
31, 2017, at 9:00 A.M. Pacific Time (the Annual Meeting) and
reconvene the Annual Meeting on Friday, June 2, 2017, at 9:00
A.M. Pacific Time, at the Companys executive offices at 2929
Seventh Street, Suite 100, Berkeley, California 94710. This
supplement to proxy statement (Supplement), supplements the proxy
statement dated April 21, 2017 (Proxy Statement) previously made
available to stockholders in connection with the solicitation by
the Board of Directors of proxies to be voted at the Annual
Meeting.
THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY
STATEMENT.
|
The purpose of this Supplement is to clarify the voting |
As originally described in the Proxy Statement, shareholder
approval of Proposal 3 requires the affirmative vote of a
majority of the outstanding shares. This Supplement clarifies
that because we believe this proposal is deemed routine, if you
are a beneficial owner and do not instruct your broker, bank, or
other agent how to vote your shares, brokers and nominees can use
their discretion to vote uninstructed. Accordingly, your broker
or nominee may vote your shares on Proposal 3.
Supplement to Proxy Statement
The last sentence under Beneficial Owner: Shares Registered in
the Name of Broker or Bank on page 3 is amended to read as
follows: Accordingly, your broker or nominee may not vote your
shares on Proposals 1, 2, 4 or 5 without your instructions, but
may vote your shares on Proposals 3 and 6.
Furthermore, the third bullet point under How many votes are
needed to approve each proposal? on page 5 is amended to read as
follows:
Proposal 3, to amend the Companys Charter to increase the
authorized number of shares of common stock from 69,500,000 to
139,000,000, must receive For votes from the holders, either in
person or by proxy, of a majority of the outstanding shares. If
you return your proxy and select Abstain, it will have the same
effect as an Against vote. As Proposal 3 is considered a routine
matter, we do not expect to receive any broker non-votes.
Similarly, the last sentence under PROPOSAL 3, on page 30 is
amended to read as follows: Abstentions will be counted toward
the tabulation of votes cast on proposals presented to the
stockholders and will have the same effect as negative votes.
This Supplement should be read together with the Proxy Statement.
Except as described in this Supplement, no other provisions or
proposals to be acted upon contained in the Proxy Statement have
been amended, and the information contained in this Supplement
replaces and supersedes any inconsistent information in the Proxy
Statement.
About Dynavax Technologies Corporation (NASDAQ:DVAX)
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage. Dynavax Technologies Corporation (NASDAQ:DVAX) Recent Trading Information
Dynavax Technologies Corporation (NASDAQ:DVAX) closed its last trading session down -0.10 at 5.60 with 553,849 shares trading hands.
